Prosecution Insights
Last updated: August 18, 2026
Application No. 18/552,760

DIAGNOSTIC METHODS OF PROSTATE CANCER

Non-Final OA §103§112
Filed
Sep 27, 2023
Priority
Apr 02, 2021 — EU 21305432.3 +1 more
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novartis AG
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
417 granted / 902 resolved
-13.8% vs TC avg
Strong +22% interview lift
Without
With
+22.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
33 currently pending
Career history
955
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.7%
+2.7% vs TC avg
§102
22.1%
-17.9% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 902 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of group I claims 1-9 in the reply filed on 5/29/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the phrase “particularly" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 2, the phrase “preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 6, the phrase “for example" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 7, the phrase “typically" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claims 3-5 and 8-9 incorporate the indefiniteness by dependency. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Behr et al, cited by applicants, in view of Afshar-Oromieh et al., cited by applicants. Behr teaches CTT1057, the same compound of claim 4, an agent targeting PSMA, to study patients with prostate cancer; the agent was administered intravenously as a solution with ~362 MBq (reading on concentration in claims 6-7) and imaged with PET. See entire disclosure, especially abstract and Fig. 1. Regarding claim 8, CTT1057 was imaged at periods within the claimed time range. See Fig 3. Behr while teaching use of CTT1057 to image and diagnose prostate cancer with PET is silent with respect to a patient population that has been diagnosed with biochemical recurrence of prostate cancer. Afshar-Oromieh is used primarily for its disclosure that PSMA targeted imaging agents were already well known to be useful in diagnosing recurrent prostate cancer. See entire disclosure, especially abstract. Alshar-Oromieh noted that increased levels of PSA usually indicate progressive disease. See page 915 left col. 2nd ¶. Since Behr teaches use of the PSMA targeting agent CTT1057 to image prostrate cancer and Afshar-Oromeih teaches that other PSMA targeting imaging agents could diagnose recurrent prostate cancer one of ordinary skill in the art would have a very high expectation of success in using CTT1057 to diagnose recurrent prostrate cancer by PET imaging. An “obvious to try” rationale may support a conclusion that a claim would have been obvious where one skilled in the art is choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success. “ [A] person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely that product [was] not of innovation but of ordinary skill and common sense. KSRInternational Co. v. Teleflex Inc., 550 U.S. ___, ___, 82 USPQ2d 1385, 1397 (2007). Thus the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/ Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Sep 27, 2023
Application Filed
Jul 30, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12685779
COMPLEX
1y 4m to grant Granted Jul 21, 2026
Patent 12673104
CLEAVABLE POLYMER DRUG CONJUGATES
7y 6m to grant Granted Jul 07, 2026
Patent 12673121
RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGING
2y 7m to grant Granted Jul 07, 2026
Patent 12653911
STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS
4y 4m to grant Granted Jun 16, 2026
Patent 12649008
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
3y 0m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
68%
With Interview (+22.1%)
3y 10m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 902 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month